Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease
- 27 June 2026
- journal article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (8) , 1439-1451
Abstract
Background: Death receptor 3 (DR3; also termed tumor necrosis factor receptor superfamily member 25 [TNFRSF25]) is the sole functional receptor for tumor necrosis factor (TNF)–like cytokine 1A (TL1A) and is constitutively expressed on effector lymphoid cells in peripheral blood and in both inflamed and adjacent noninflamed tissues. Excessive DR3 signaling contributes to chronic inflammation in inflammatory bowel disease (IBD). While clinical trials of anti-TL1A antibodies have demonstrated efficacy in ulcerative colitis and Crohn disease, the stable expression pattern of DR3 suggests that receptor blockade may more effectively and durably inhibit TL1A-driven proinflammatory signaling and limit disease propagation. We describe the preclinical development of SL-325, a fully human, Fc-silent, high-affinity DR3-blocking monoclonal antibody. Methods: Binding affinity and specificity of SL-325 were evaluated using biophysical and cell-based assays. Functional activity was assessed in peripheral blood mononuclear cells (PBMCs) from healthy donors and IBD patients, an ex vivo human intestinal inflammation model, and cynomolgus macaque toxicology studies. Results: SL-325 bound to human DR3 with picomolar affinity and high specificity while potently blocking TL1A binding without inducing DR3 agonism. SL-325 suppressed TL1A-induced proinflammatory cytokine secretion in PBMCs from healthy donors and IBD patients. In an ex vivo human intestinal model, SL-325 inhibited TL1A-driven cytokine production and preserved epithelial barrier integrity. In nonhuman primates, SL-325 was safe and well tolerated at doses up to 100 mg/kg, demonstrated dose-proportional pharmacokinetics, and led to prolonged DR3 receptor occupancy (RO) without immune activation or proliferation. Conclusion: These data demonstrate that SL-325 is a novel DR3-blocking antibody with the potential to provide durable inhibition of the TL1A/DR3 axis and support the clinical development of SL-325 to treat IBD.Keywords
Funding Information
- Shattuck Labs, Inc
This publication has 31 references indexed in Scilit:
- Tu1460 TL1A DRIVES TH1, TH2 AND TH17 PATHWAYS IN HUMAN LAMINA PROPRIA CELLS IN IBDGastroenterology, 2026
- Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trialThe Lancet Gastroenterology & Hepatology, 2025
- A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3Scientific Reports, 2022
- Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosisClinical Rheumatology, 2017
- Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis, Crohn’s disease and leprosyScientific Reports, 2016
- Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL‐22 production and IL‐2‐dependent proliferationEuropean Journal of Immunology, 2015
- Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritisHuman Immunology, 2014
- Immunobiology of TNFSF15 and TNFRSF25Immunologic Research, 2013
- Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasiaMucosal Immunology, 2010
- TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell CostimulatorImmunity, 2002